The two-year shortage of Eli Lilly’s blockbuster weight ... compounding pharmacies that make weight-loss drugs, but they do not test the products. There is no FDA-approved generic version ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.

(Bloomberg) -- Eli Lilly & Co.’s diabetes and weight-loss drugs Mounjaro and ... The FDA said in October that there was no longer a shortage of Lilly’s drugs and that making copies must ...

On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss ... agency's shortage list. Now that the FDA has decided tirzepatide is no longer ...

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

A federal judge has sided with the U.S. Food and Drug Administration over a decision last year to remove two Eli Lilly drugs — the Zepbound weight loss medicine ... will no longer have access ...

A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and diabetes drugs Zepbound and Mounjaro off a list of medicines in short supply, ...

All doses of Eli Lilly’s weight loss drugs Zepbound and Mounjaro are available in the United States after more than a year of being in shortage, according to the Food and Drug Administration’s ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in ...

The shortage of Eli Lilly and Co.’s blockbuster weight-loss and diabetes drugs is over ... “They are being cut off cold-turkey, their prescription no longer fillable,” he said in a statement.

News weighs on stocks of companies offering alternatives and some smaller ones developing their own drugs ... Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no ...